Clinical trials: Non Hodgkin Lymphoma
Lymphoma, Malignant, Hodgkin's Lymphoma
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
- Conditions
- Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
- Trial name
- NCT00741871
- Testing
- SB1518
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- S*BIO
Hepatosplenic T-cell Lymphoma
Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands
The purpose of this study is to examine reports of the cancer called hepatosplenic T-cell lymphoma (HSTCL) in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief or PALGA) during…
- Trial name
- NCT00731536
- Testing
- No intervention
- Where
- 10 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Trial name
- CARCD30 (NCT01192464)
- Testing
- autologous CAR.CD30 EBV specific-CTLs
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Baylor College of Medicine
Lymphoma, B-Cell
Retreatment With CTL019/CTL119
This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
- Trial name
- NCT04419909
- Testing
- CD19 redirected autologous T cells (CTL019 or CTL119 cells)
- Where
- United States
- Sponsor
- University of Pennsylvania
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Ptosis, Ptosis, Mild
Performance and Safety Assessment of SPRING THREAD® Elastic Tensor Thread in Patients With Mild to Moderate Facial Ptosis.
The purpose of this post-market clinical follow up study is to assess the safety and effectiveness of the SPRING THREAD® elastic tensor thread.
- Trial name
- ESTES (NCT05746078)
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- 1st SurgiConcept
Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).
- Conditions
- Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma, Primary Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- VISMOLY (NCT01944943)
- Testing
- Vismodegib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- The Lymphoma Academic Research Organisation
Lymphoma,Non-Hodgkin
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have…
- Trial name
- CHRONOS-3 (NCT02367040)
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Rituximab
- Where
- 187 sites in United States, Argentina and 35 more
- Volunteers
- 458 people
- Sponsor
- Bayer
CLL, SLL
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.
- Conditions
- CLL, SLL, Richter's Transformation, Indolent Lymphoma
- Trial name
- NCT04806035
- Testing
- TG-1801, Ublituximab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00028717
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 13 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Mantle-Cell Lymphoma
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
- Trial name
- SYMPATICO (NCT03112174)
- Testing
- Ibrutinib, Venetoclax
- Where
- 120 sites in United States, Australia and 15 more
- Volunteers
- 366 people
- Sponsor
- Pharmacyclics LLC.
Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma.
- Conditions
- Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma
- Trial name
- APOLLO (NCT05798897)
- Testing
- MT-601
- Where
- 7 sites in United States
- Volunteers
- 79 people
- Sponsor
- Marker Therapeutics, Inc.
B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's…
- Conditions
- B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT01351935
- Testing
- AVL-292
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin, Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a…
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- TAPUR (NCT02693535)
- Testing
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Where
- 181 sites in United States, Puerto Rico
- Volunteers
- 4,200 people
- Sponsor
- American Society of Clinical Oncology
Diffuse Large B Cell Lymphoma (DLBCL)
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen…
- Trial name
- NCT06647940
- Testing
- Orelabrutinib Oral Tablet, R-CHOP Protocol
- Where
- 11 sites in China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Diffuse Large B Cell Lymphoma
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
This is a phase I/II open label, multi-center study of azacytidine in combination with standard RCHOP therapy in patients with DLBCL.
- Trial name
- NCT01004991
- Testing
- rituximab, cyclophosphamide, vincristine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Acute Lymphoblastic Leukemia, Leukemia Acute Myeloid - AML
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT
Allocation: Non-Randomized Endpoint Classification: Safety/Feasibility Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Study to assess the feasibility and safety of the infusion of a T…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia Acute Myeloid - AML, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT01810120
- Testing
- TCR alfa beta T cell depletion
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Mariella Enoc
Breast Cancer, Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is metastatic to the skin.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer
- Trial name
- NCT00023790
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Follicular
Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
The purpose of this study was to evaluate the safety and efficacy of ofatumumab and bendamustine combination therapy in patients with indolent B-cell NHL that did not respond to rituximab or a rituximab-containing regimen during…
- Trial name
- A+B (NCT01077518)
- Testing
- Ofatumumab, Bendamustine infusion, Ofatumumab and Bendamustine infusions (Arm A)
- Where
- 140 sites in United States, Argentina and 15 more
- Volunteers
- 346 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Use Disorder, Opioid Use Disorder, Moderate
TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization
The primary objective of this study is to evaluate the ability of TRTME to increase initiation of MOUD outpatient treatment and MOUD knowledge in hospitalized patients with OUD deemed to be good candidates for MOUD by the UCMC…
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Trial name
- TRTME (NCT07780097)
- Testing
- TRTME
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- T. John Winhusen, PhD
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.